Gonadal & Ovarian Pharmacology

Correct Answer

C — Leuprolide acetate

Rationale

Leuprolide acetate is a synthetic gonadotropin-releasing hormone agonist that resists enzymatic degradation and produces continuous rather than pulsatile receptor stimulation. It is available as depot injectable formulations at 1-, 3-, and 6-month intervals. Elagolix is a gonadotropin-releasing hormone antagonist, not an agonist. Raloxifene is a selective estrogen receptor modulator. Anastrozole is an aromatase inhibitor.

Correct Answer

D — Elagolix

Rationale

Elagolix (Orilissa) is classified as an oral gonadotropin-releasing hormone antagonist. It produces immediate competitive receptor blockade and is taken as a daily oral tablet, making it distinct from the injectable or implant formulations used for gonadotropin-releasing hormone agonists. Leuprolide acetate and goserelin acetate are gonadotropin-releasing hormone agonists, not antagonists. Nafarelin acetate is a gonadotropin-releasing hormone agonist administered as an intranasal spray.

Correct Answer

B — Ospemifene

Rationale

Ospemifene is a selective estrogen receptor modulator approved for moderate to severe dyspareunia due to vulvovaginal atrophy in postmenopausal women. Like tamoxifen and raloxifene, it produces tissue-selective estrogen receptor agonist or antagonist effects depending on the target tissue. Leuprolide acetate is a gonadotropin-releasing hormone agonist. Medroxyprogesterone acetate is a synthetic progestin. Conjugated equine estrogens are a mixture of estrogen sulfates, not a selective estrogen receptor modulator.

Correct Answer

A — Nafarelin acetate

Rationale

Nafarelin acetate is the gonadotropin-releasing hormone agonist formulated as an intranasal spray, administered by nasal inhalation twice daily. It achieves systemic absorption through the nasal mucosa. Leuprolide acetate is available as depot intramuscular or subcutaneous injectable formulations. Goserelin acetate is implanted as a subcutaneous biodegradable depot. Elagolix is an oral gonadotropin-releasing hormone antagonist, not an agonist.

Correct Answer

D — Conjugated equine estrogens

Rationale

Conjugated equine estrogens (Premarin) are classified as a mixture of water-soluble estrogen sulfates extracted from the urine of pregnant mares. The mixture contains several estrogens not naturally present in humans, including equilin and equilenin. Ethinyl estradiol is a synthetic estrogen with a C-17 chemical modification that improves oral bioavailability. Micronized 17-beta-estradiol is the bioidentical natural human estrogen formulated as small particles for oral absorption. Estriol is the weakest of the three natural human estrogens, produced primarily by the placenta during pregnancy.

Correct Answer

C — Venlafaxine

Rationale

Venlafaxine is classified as a serotonin-norepinephrine reuptake inhibitor. It blocks reuptake of both serotonin and norepinephrine. Paroxetine and fluoxetine are classified as selective serotonin reuptake inhibitors — they block primarily serotonin reuptake. Gabapentin is classified as an alpha-2-delta calcium channel ligand, used for neuropathic pain and as an off-label treatment for vasomotor symptoms.

Correct Answer

B — Before receptor downregulation occurs, continuous agonist stimulation paradoxically increases luteinizing hormone, follicle-stimulating hormone, and sex hormone secretion for 1 to 2 weeks

Rationale

Gonadotropin-releasing hormone agonists resist enzymatic degradation and produce continuous rather than pulsatile receptor stimulation. The pituitary, however, does not downregulate immediately. During the first 1 to 2 weeks of treatment, continuous agonist stimulation paradoxically increases luteinizing hormone, follicle-stimulating hormone, and sex hormone release — a flare effect. In women with endometriosis, this transient sex hormone rise can temporarily stimulate ectopic implants and worsen pelvic pain. The flare resolves as receptor downregulation and pituitary desensitization develop over 2 to 4 weeks, after which gonadal sex hormones fall to suppressed levels.

Correct Answer

D — Continuous non-pulsatile receptor occupation causes receptor downregulation and pituitary desensitization, so the receptor no longer transduces the agonist signal into gonadotropin release

Rationale

Endogenous gonadotropin-releasing hormone is released from the hypothalamus in pulses every 60 to 120 minutes; this pulsatile pattern is required for sustained pituitary gonadotropin secretion. Gonadotropin-releasing hormone agonists are resistant to degradation and produce continuous, non-pulsatile receptor stimulation. This sustained occupation causes the gonadotropin-releasing hormone receptor to internalize and downregulate — the pituitary gonadotroph cells become desensitized and stop responding to the constant signal. After 2 to 4 weeks, luteinizing hormone and follicle-stimulating hormone secretion falls to castrate levels. The suppression is pharmacological and fully reversible on discontinuation.

Correct Answer

A — Clinically significant bone mineral density loss occurs beyond 6 months of the hypoestrogenic state produced by gonadotropin-releasing hormone agonist monotherapy

Rationale

Gonadotropin-releasing hormone agonist therapy suppresses ovarian estradiol production, creating a hypoestrogenic state equivalent to surgical menopause. Estradiol is a key driver of bone mineral accrual and maintenance. Without adequate estrogen, bone resorption exceeds formation and bone mineral density falls progressively. This loss becomes clinically significant within 6 months of monotherapy, establishing 6 months as the generally accepted maximum duration for gonadotropin-releasing hormone agonist use without add-back estrogen. Add-back therapy restores enough estrogen to protect bone and reduce vasomotor symptoms while maintaining adequate disease suppression, allowing safe extension of treatment beyond this limit.

Correct Answer

C — Endometriotic tissue and fibroids require higher estrogen concentrations to remain stimulated than bone and brain require for protection, allowing a low add-back dose to protect without restimulating disease

Rationale

Add-back therapy exploits a differential estrogen threshold: endometriotic implants require higher circulating estrogen concentrations to be stimulated than bone and the central nervous system require for protection. A low add-back dose that is insufficient to stimulate ectopic endometrial tissue can still activate bone estrogen receptors and maintain bone mineral density, and can reduce vasomotor symptoms driven by hypothalamic estrogen receptor activity. This allows the physician to extend gonadotropin-releasing hormone agonist treatment from the 6-month monotherapy limit to 12 months or longer while preserving bone density and quality of life.

Correct Answer

B — Venous thromboembolism, because raloxifene carries a thrombotic risk similar to oral estrogen despite being a selective estrogen receptor modulator

Rationale

Raloxifene is a selective estrogen receptor modulator that antagonizes the estrogen receptor in both breast and uterus, making it safe from an endometrial cancer standpoint. However, like oral estrogen, raloxifene carries a venous thromboembolism risk — the absolute risk is similar to that of oral hormone therapy. The precise mechanism differs from estrogen-driven coagulation factor induction, but the clinical consequence is the same: raloxifene is contraindicated in women with active or prior venous thromboembolism. This is a clinically important distinction because patients and prescribers sometimes assume that a non-estrogen agent carries no thrombotic risk.

Correct Answer

D — Gonadotropin-releasing hormone antagonists competitively block the receptor from the first dose, preventing endogenous gonadotropin-releasing hormone from stimulating the pituitary, without any initial stimulatory phase

Rationale

The mechanistic distinction is fundamental. Gonadotropin-releasing hormone agonists must first stimulate the receptor — producing an initial flare — and then wait for receptor downregulation and desensitization to develop before suppression is achieved, a process taking 2 to 4 weeks. Gonadotropin-releasing hormone antagonists, by contrast, competitively occupy and block the receptor immediately, preventing endogenous gonadotropin-releasing hormone from binding and stimulating the pituitary from the very first dose. There is no initial stimulatory phase and no flare. Luteinizing hormone and follicle-stimulating hormone fall within hours of the first dose. Cessation of therapy allows rapid receptor recovery and return of gonadotropin secretion.

Correct Answer

A — Medroxyprogesterone acetate, because the trial arm that showed increased breast cancer used conjugated equine estrogens plus medroxyprogesterone acetate, while the estrogen-alone arm showed no breast cancer increase

Rationale

The Women's Health Initiative comprised two parallel trials. The arm combining conjugated equine estrogens with medroxyprogesterone acetate — given to women with an intact uterus — was stopped early when breast cancer incidence crossed the predefined threshold. The arm using conjugated equine estrogens alone — given to hysterectomized women — showed no increase in breast cancer and a non-significant trend toward reduction. Because the only pharmacological difference between the two arms was the addition of medroxyprogesterone acetate, the breast cancer signal is attributable to the progestin component, not to estrogen alone. This distinction is pharmacologically important for counseling women about hormone therapy regimen selection.

Correct Answer

C — Women who begin hormone therapy more than 10 years after menopause or after age 60 show net cardiovascular harm, particularly increased coronary events and stroke, whereas earlier initiation is associated with a neutral or favorable cardiovascular profile

Rationale

The cardiovascular risk-benefit of hormone therapy depends on the timing of initiation relative to menopause — the timing hypothesis. Women who begin hormone therapy within 10 years of menopause onset, or before age 60, show a neutral or favorable cardiovascular profile. Women who begin more than 10 years after menopause, or after age 60, show net cardiovascular harm, particularly increased coronary events and stroke. This pattern likely reflects the state of the vascular endothelium: estrogen has protective effects on healthy endothelium, but in the presence of established atherosclerosis — which progresses silently during estrogen deprivation — estrogen may destabilize plaques. This woman is 65, approximately 13 years post-menopause, placing her initiation outside the favorable window.

Correct Answer

A — During the first 1 to 2 weeks of gonadotropin-releasing hormone agonist therapy, receptor downregulation has not yet occurred and continuous agonist stimulation produces a testosterone flare; in high-volume disease this surge can precipitate spinal cord compression or severe pain crisis

Rationale

Gonadotropin-releasing hormone agonists produce a paradoxical testosterone flare during the first 1 to 2 weeks of therapy, before receptor downregulation causes suppression. In most men with prostate cancer, this transient testosterone rise is clinically manageable. In men with high-volume metastatic disease involving the spine, however, the testosterone flare can stimulate tumor growth sufficiently to precipitate spinal cord compression, pain crisis, or ureteral obstruction. Bicalutamide, an androgen receptor antagonist, blocks peripheral testosterone action at the tumor cell without affecting the testosterone level itself, providing protection during the flare window. Once receptor downregulation is established and testosterone is suppressed at approximately 4 weeks, the antiandrogen is discontinued.

Correct Answer

C — Systemic estrogen without a progestin produces unopposed endometrial stimulation, causing progressive proliferation and hyperplasia in women with an intact uterus

Rationale

Estrogen drives endometrial proliferation through estrogen receptor alpha activation. In the natural menstrual cycle, progesterone secreted by the corpus luteum after ovulation opposes this proliferative effect, maintaining endometrial stability. In postmenopausal women receiving systemic estrogen without a progestin, there is no endogenous progesterone to counteract ongoing estrogenic stimulation. Progressive unopposed estrogen exposure leads to endometrial hyperplasia and, with prolonged use, substantially increases the risk of endometrial carcinoma. Women with an intact uterus must receive a progestin alongside systemic estrogen in any hormone therapy regimen. Women who have had a hysterectomy do not require progestin — the absent uterus eliminates endometrial cancer risk.

Correct Answer

B — The higher dose produces near-complete estrogen suppression equivalent to a gonadotropin-releasing hormone agonist, generating a more severe and progressive bone mineral density loss that limits safe use to 6 months

Rationale

Elagolix is a dose-titratable oral gonadotropin-releasing hormone antagonist. At the lower approved dose, it produces partial estrogen suppression into the low-normal premenopausal range — sufficient to reduce endometriosis pain while preserving enough estrogen to limit bone mineral density loss, allowing use for up to 24 months. At the higher approved dose, elagolix produces near-complete estrogen suppression approaching the castrate levels achieved with gonadotropin-releasing hormone agonists. This greater degree of hypoestrogenism produces more pronounced and progressive bone mineral density loss, limiting the approved duration to 6 months. The dose-dependent trade-off is therefore between greater pain efficacy at the high dose and better bone preservation at the low dose. For women requiring the high dose, the 6-month limit means surgery or an alternative long-term strategy must be planned.

Correct Answer

D — Fibroid volume reduction depends entirely on sustained hypoestrogenism and reverses rapidly when therapy stops, and prolonged monotherapy causes progressive bone mineral density loss that limits use to a preoperative bridge

Rationale

Uterine fibroids are estrogen- and progesterone-dependent benign smooth muscle tumors. Gonadotropin-releasing hormone agonist therapy reduces fibroid volume by producing pharmacological hypoestrogenism, causing ischemic atrophy of fibroid tissue. This volume reduction is entirely dependent on sustained hormone suppression and is not a permanent structural change. When the agonist is stopped, estradiol returns to premenopausal levels and fibroids return to approximately their pre-treatment volume rapidly — often within months. Additionally, gonadotropin-releasing hormone agonist monotherapy cannot be safely maintained beyond 6 months without add-back due to progressive bone mineral density loss. For these reasons, gonadotropin-releasing hormone agonists are used as a preoperative bridge to reduce fibroid volume, correct preoperative anemia, and facilitate less invasive surgery — not as definitive standalone treatment.